Poison Or Antibiotic? a Guide to "Class" Entries

Total Page:16

File Type:pdf, Size:1020Kb

Poison Or Antibiotic? a Guide to Poison or Antibiotic? A Guide to “Class” Entries Preface Most entries in the Poisons List, i.e. the Schedule 10, and the Schedules 1, 2 and 3 to the Pharmacy and Poisons Regulations (Cap. 138A) are in the form of individual drugs and their salts, e.g. “Abacavir; its salts”. However, some entries are in the form of a “class”, e.g. “Barbituric acid; its salts; its derivatives …”. In such cases, it is not always clear which drugs are members of the class (e.g. amobarbital, barbital, pentobarbital, phenobarbital, etc. are poisons, being derivatives of barbituric acid). Likewise, the Antibiotics Ordinance (Cap. 137) applies to the substances specified in Schedule 1 to the Antibiotics Regulations, to their salts and derivatives, and to the salts of such derivatives. Again, it is not always clear which drugs are derivatives of an antibiotic named in the Schedule (e.g. demeclocycline, doxycycline, tigecycline, etc. are antibiotics, being derivatives of “Tetracycline” named in the Schedule). This Guide provides a list of such drugs which are available as registered pharmaceutical products in Hong Kong. Drugs which are not available as registered pharmaceutical products in Hong Kong are also included in this Guide as far as possible. It should be noted that it is not possible to compile a complete list of all these drugs, simply because there is no limit to the number of “derivatives” a parent chemical can have. This Guide should be read in conjunction with the Schedules 1, 2, 3, and 10 to the Pharmacy and Poisons Regulations, and Schedule 1 to the Antibiotics Regulations, if the poison/antibiotic classification of a particular pharmaceutical product is to be determined. Drug Office Department of Health February 2021 1 Step-by-step guidance on determining the poison/antibiotic classification of a pharmaceutical product 1. Identify the (first) drug contained in the pharmaceutical product. 2. If this drug is found in the Poisons List, i.e. the Schedule 10, continue to look for it in the Schedules 1 and 3 to the Pharmacy and Poisons Regulations to determine the “poison” classification of the pharmaceutical product containing this drug. Then look for it in the Schedule 2 to determine if the product is exempted from control as poison under that Schedule. 3. If the drug is not found in the Poisons List, look for it in Schedule 1 to the Antibiotics Regulations. 4. If the drug is found in Schedule 1, the pharmaceutical product will be an antibiotic. 5. If the drug is found neither in the Poisons List nor in Schedule 1 to the Antibiotics Regulations, look for it in the Index to the Guide. 6. If the drug is found in the Index to the Guide, note the Item Number against it, then turn to the Guide itself to identify the Item number and the corresponding Entry in the Poisons List or Antibiotics Schedule of the drug. 7. Repeat steps 2 to 5 with respect to this entry, to determine the classification of the pharmaceutical product containing this drug. 8. If the drug is not found in the Index to the Guide, look for its synonyms (in “Martindale”, the Merck Index, etc), and repeat steps 2 to 7 with respect to each synonym. 9. If none of the synonyms is found in the Index to the Guide after repeating steps 2 to 7, the pharmaceutical product containing the drug will probably be neither a poison nor an antibiotic. However, as mentioned above, the list may not be exhaustive and the actual classification of a product always dictated by the legislations. In addition, the product may also fall under the control of other Ordinances such as Dangerous Drugs Ordinance (Cap. 134). 10. For a multi-component product, repeat the above steps with respect to each component. The “poison” classification of the product itself will be that of the most stringently classified component. In addition, if one component is classified as antibiotic, the product itself will also be classified as an antibiotic. 2 Index to the Guide Drug Name Item No. Acepromazine 112 Aceprometazine 112 Acetarsol 34 Acetophenazine 112 Acetoxypregnenolone 131 Acetyl sulfamethoxypyrazine 25 Acetyldigitoxin 64 Acetyldigoxin 64 Acetyldihydrocodeinone 66 Acetylkitasamycin 49 Acetylmethadol 69 Aconitine 5 Adefovir dipivoxil 2 Adiphenine 24 Adrenaline 131 Ajmaline 19 Alatrofloxacin 138 Albutrepenonacog alfa 43 Alcaftadine 32 Alclofenac monoethanolamine 4 Alclometasone 131 Aldosterone 131 Alfatradiol 30 Algestone 131 Algestone acetophenide 30 Alimemazine 32 Allobarbital 38 Allyloestrenol 30 Alpha‐Chloralose 51 Alphadolone acetate 23 Alpha‐Lipoic acid 135 Alphamethadol 69 Alprazolam 62 Althiazide 54 Altizide 54 Altrenogest 30 Altretamine 80 Ambucaine 24 Amcinonide 131 Amethocaine 24 Amfepramone 100 Amikacin 90 Aminolevulinic acid hydrochloride 27 Aminopromazine 112 Aminosalicylate 29 Amitriptylinoxide 123 3 Index to the Guide Drug Name Item No. Amobarbital 38 Amodiaquin 53 Amoxicillin 109 Ampicillin 109 Amylobarbitone 38 Amylocaine 24 Androstanolone 30 Androstenediol 30 Androstenedione 30 Antihaemophilic factor 43 Antimony potassium tartrate 33 Antimony sodium gluconate 33 Aprobarbital 38 Arbekacin 90 Arbutamine 131 Arsanilic acid 34 Arsenamide 34 Arsthinol 34 Atropine methobromide 6 Atropine methonitrate 6 Azaclorzine 112 Azaribine 35 Azatadine 32 Azathioprine 94 Azidamphenicol 52 Azilsartan kamedoxomil 36 Azilsartan medoxomil 36 Azithromycin 72 Azosemide 56 Aztreonam 109 Bacampicillin 109 Bamipine 32 Barbital 38 Barbitone 38 Beclomethasone 131 Bekanamycin 90 Bemetizide 54 Bendamustine 103 Bendrofluazide 54 Bendroflumethiazide 54 Benfluorex 100 Benmoxine 81 Benoxinate 24 Benperidol 79 Benzathine Benzylpenicillin 109 Benzestrol 30 4 Index to the Guide Drug Name Item No. Benzocaine 26 Benzodepa 37 Benzoylpas 29 Benzphetamine 100 Benzthiazide 54 Benzylhydrochlorothiazide 54 Benzylpenicillin 109 Benzylsulfamide 25 Bepotastine 32 Betamethadol 69 Betamethasone 131 Bisulepin 32 Boldenone 30 Brallobarbital 38 Bromazepam 62 Bromazine 32 Bromodiphenhydramine 32 Bromperidol 79 Brompheniramine 32 Bromvalerylurea 44 Broparestrol 30 Budesonide 131 Bufotenine 84 Butabarbital 38 Butacaine 26 Butalbital 38 Butamben 26 Butaperazine 112 Butethamate 24 Butethamine 26 Buthiazide 54 Butizide 54 Butobarbital 38 Butoxycaine 24 Butriptyline 123 Butropium 15 Butyl aminobenzoate 26 Cacodylate 34 Cafedrine 100 Calcitonin 136 Camazepam 62 Candesartan cilexetil 47 Canfosfamide 103 Carbarsone 34 Carbenicillin 109 Carbetocin 108 5 Index to the Guide Drug Name Item No. Carbinoxamine 32 Carbocloral 51 Carboprost 122 Carboquone 37 Carfecillin 109 Carfenazine 112 Cargutocin 108 Carindacillin 109 Carmofur 74 Carphenazine 112 Cathine 11 Cefaclor 50 Cefadroxil 50 Cefalexin 50 Cefaloridine 50 Cefalotin 50 Cefamandole 50 Cefapirin 50 Cefatrizine 50 Cefazedone 50 Cefcapene 50 Cefdinir 50 Cefditoren 50 Cefepime 50 Cefetamet 50 Cefixime 50 Cefmenoxime 50 Cefminox 50 Cefodizime 50 Cefonicid 50 Cefoperazone 50 Ceforanide 50 Cefoselis 50 Cefotaxime 50 Cefotiam 50 Cefpimizole 50 Cefpiramide 50 Cefpirome 50 Cefpodoxime 50 Cefprozil 50 Cefradine 50 Cefroxadine 50 Cefsulodin 50 Ceftazidime 50 Ceftibuten 50 Ceftiofur 50 6 Index to the Guide Drug Name Item No. Ceftizoxime 50 Ceftolozane 50 Ceftriaxone 50 Cetirizine 32 Chloral betaine 51 Chloral hydrate 51 Chlorambucil 103 Chloraminophenamide 56 Chlormadinone acetate 30 Chlornaphazine 103 Chloroprednisone 131 Chloroprocaine 24 Chloropyramine 31 Chlorothen 31 Chlorotrianisene 30 Chlorphenamide 56 Chlorpheniramine 32 Chlorproethazine 112 Chlorpromazine 112 Choline theophyllinate 134 Ciclesonide 131 Cidoxepin 71 Cimetropium bromide 14 Cinchocaine 83 Cinchophen 114 Cinnarizine 32 Clarithromycin 72 Clemastine 32 Clemizole 32 Clindamycin 92 Clobetasol 131 Clobetasone 131 Clocapramine 58 Clocinizine 32 Clocortolone 131 Clonazepam 62 Clopamide 56 Clopenthixol 55 Cloprednol 131 Cloprostenol 122 Clorazepate 62 Clostebol 30 Cloxacillin 109 Cloxazolam 62 Cloxotestosterone 30 Cocaethylene 10 7 Index to the Guide Drug Name Item No. Codoxime 65 Colchicine 8 Colistimethate sodium 60 Colpormon 30 Combelen 112 Cortisone 131 Cortivazol 131 Crotarbital 38 Cyacetacide 82 Cyamemazine 112 Cyclobarbital 38 Cyclodrine 24 Cyclomethycaine 24 Cyclopenthiazide 54 Cyclopentobarbital 38 Cyclopentolate 24 Cyclophosphamide 103 Cyclothiazide 54 Cymarin 129 Cyproheptadine 32 Cyproterone 30 Dalfopristin 119 Danazol 30 Deanol benzilate 24 Decamethonium bromide 118 Deflazacort 131 Defosfamide 103 Delmadinone acetate 30 Delorazepam 62 Demeclocycline 133 Demegestone 30 Demoxytocin 108 Denopterin 28 Deoxycorticosterone 131 Deprenyl 100 Deptropine 32 Deserpidine 19 Deslanoside 64 Desmopressin 142 Desogestrel 30 Desonide 131 Desoxymethasone 131 Dexamethasone 131 Dexbrompheniramine 32 Dexchlorpheniramine 32 Dextromethorphan 96 8 Index to the Guide Drug Name Item No. Dextropropoxyphene 120 Dextrorphan 85 Diacetyldihydromorphine 67 Diacetylmorphine 17 Diaziquone 37 Dibekacin 90 Dichloralphenazone 51 Dichlorisone 131 Dichlorphenamide 56 Dicloxacillin 109 Dienoestrol 30 Dienogest 30 Diethazine 112 Diethylpropion 100 Diethylstilbestrol 30 Diethylthiambutene 70 Diflorasone 131 Diflucortolone 131 Difluprednate 131 Digitalin 64 Digitoxin 64 Digoxin 64 Dihydrostreptomycin 128 Diisopropanolamine felbinac 40 Dimenhydrinate 31 Dimethisterone 30 Dimethocaine 26 Dimethylaminoethyl reserpilinate 19 Dimethylthiambutene 70 Dimetindene 32 Dimetofrine 131 Diphenylpyraline 32 Dipivefrin 131 Dipyrone 105 Dirithromycin 72 Divalproex sodium 140 Dixyrazine 112 d‐Norpseudoephedrine 11 Doxifluridine 74 Doxorubicin 3 Doxycycline 133 Drosprienone 30 Drostanolone 30 Dydrogesterone
Recommended publications
  • (12) United States Patent (10) Patent No.: US 7,871,995 B2 Bunschoten Et Al
    US00787 1995 B2 (12) United States Patent (10) Patent No.: US 7,871,995 B2 Bunschoten et al. (45) Date of Patent: *Jan. 18, 2011 (54) DRUG DELIVERY SYSTEM COMPRISINGA (52) U.S. Cl. ....................................... 514/171; 514/182 TETRAHYDROXYLATED ESTROGEN FOR (58) Field of Classification Search ................. 514/171, USE IN HORMONAL CONTRACEPTION 514f182 See application file for complete search history. (75) Inventors: Evert Johannes Bunschoten, Heesch (NL); Herman Jan Tijmen Coelingh (56) References Cited Bennink, Driebergen (NL); Christian U.S. PATENT DOCUMENTS Franz Holinka, New York, NY (US) 3,440,320 A 4, 1969 Sackler et al. O O 3,797.494. A 3, 1974 Zaffaroni (73) Assignee: Pantarhei Bioscience B.V., Al Zeist 4,460.372 A 7/1984 Campbell et al. (NL) 4,573.996 A 3/1986 Kwiatek et al. 4,624,665 A 1 1/1986 Nuwayser (*) Notice: Subject to any disclaimer, the term of this 4,722,941 A 2f1988 Eckert et al. patent is extended or adjusted under 35 4,762,717 A 8/1988 Crowley, Jr. U.S.C. 154(b) by 1233 days. 4.937,238 A 6, 1990 Lemon 5,063,507 A 1 1/1991 Lindsey et al. This patent is Subject to a terminal dis- 5,130,137 A 7/1992 Crowley, Jr. claimer. 5,211,952 A 5/1993 Spicer et al. 5,223,261 A 6/1993 Nelson et al. 5,340,584 A 8/1994 Spicer et al. (21) Appl. No.: 10/478,357 5,340,585 A 8/1994 Pike et al. 1-1. 5,340,586 A 8, 1994 Pike et al.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Abecarnil/Allobarbital 959 Pharmacopoeias
    Abecarnil/Allobarbital 959 Pharmacopoeias. In Eur. (see p.vii). acamprosate’s action including inhibition of neuronal hyper- maleate in the treatment of anxiety disorders, hiccups, and nau- Ph. Eur. 6.2 (Acamprosate Calcium). A white or almost white excitability by antagonising excitatory amino acids such as sea and vomiting. Acepromazine, as the base, has also been giv- powder. Freely soluble in water; practically insoluble in alcohol glutamate. en in preparations for the management of insomnia. and in dichloromethane. A 5% solution in water has a pH of 5.5 1. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacol- Preparations to 7.0. ogy and clinical potential in the management of alcohol depend- ence after detoxification. Drugs 1997; 53: 1038–53. Proprietary Preparations (details are given in Part 3) Adverse Effects 2. Anonymous. Acamprosate for alcohol dependence? Drug Ther Denm.: Plegicil; Turk.: Plegicil. The main adverse effect of acamprosate is dosage-related diar- Bull 1997; 35: 70–2. Multi-ingredient: Fr.: Noctran. rhoea; nausea, vomiting, and abdominal pain occur less frequent- 3. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001; 62 (suppl ly. Other adverse effects have included pruritus, and occasionally 20): 42–8. a maculopapular rash; bullous skin reactions have occurred rare- 4. Overman GP, et al. Acamprosate for the adjunctive treatment of Aceprometazine (rINN) ly. Depression and fluctuations in libido have also been reported. alcohol dependence. Ann Pharmacother 2003; 37: 1090–9. Hypersensitivity reactions including urticaria, angioedema, and 5. Anton RF, et al. Combined pharmacotherapies and behavioral 16-64 CB; Aceprometazina; Acéprométazine; Aceprometazi- anaphylaxis have been reported very rarely.
    [Show full text]
  • Journal of Pharmaceutical and Biomedical Analysis Stability Of
    Journal of Pharmaceutical and Biomedical Analysis 49 (2009) 519–524 Contents lists available at ScienceDirect Journal of Pharmaceutical and Biomedical Analysis journal homepage: www.elsevier.com/locate/jpba Short communication Stability of selected chlorinated thiazide diuretics K. Deventer a,∗, G. Baele b, P. Van Eenoo a, O.J. Pozo a, F.T. Delbeke a a DoCoLab, UGent, Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30, B-9052 Zwijnaarde, Belgium b Department of Applied Mathematics and Computer Science, Krijgslaan 281, S9, B-9000 Gent, Belgium article info abstract Article history: In sports, diuretics are used for two main reasons: to flush previously taken prohibited substances with Received 6 August 2008 forced diuresis and in sports where weight classes are involved to achieve acute weight loss. A com- Received in revised form 5 November 2008 mon property observed for thiazides is hydrolysis in aqueous media resulting in the formation of the Accepted 6 November 2008 degradation product aminobenzenedisulphonamide. This degradation product can be observed for sev- Available online 13 November 2008 eral thiazides. Because there is limited information regarding the effect of pH, temperature and light on the stability of thiazides, these parameters were investigated for chlorothiaizide, hydrochlorothiazide Keywords: and altizide. For all three compounds the degradation product could be detected after incubation at pH Doping ◦ Urine 9.5 for 48 h at 60 C. At lower pH and temperature the degradation product could not be detected for all Diuretics compounds. When samples were exposed to UV-light altizide and hydrochlorothiazide were photode- Thiazides graded to chlorothiazide. When the degradation rate between the different compounds was compared Sports for a given temperature and pH, altizide is the most unstable compound.
    [Show full text]
  • Treatment of Schizophrenia Course Director: Philip Janicak, M.D
    S6735- Treatment of Schizophrenia Course Director: Philip Janicak, M.D. #APAAM2016 Saturday, May 14, 2016 Marriott Marquis - Marquis Ballroom D psychiatry.org/ annualmeetingS4637 ANNUAL MEETING May 14-18, 2016 • Atlanta Reference • Janicak PG, Marder SR, Tandon R, Goldman M (Eds.). Schizophrenia: Recent Advances in Diagnosis and Treatment. New York, NY: Springer; 2014. Schizophrenia: Recent Diagnostic Advances, Neurobiology, and the Neuropharmacology of Antipsychotic Drug Therapy Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine Gainesville, Florida Annual Meeting of the American Psychiatric Association New York, New York May 3–7, 2014 Disclosure Information MEMBER, WPA PHARMACOPSYCHIATRY SECTION MEMBER, DSM-5 WORKGROUP ON PSYCHOTIC DISORDERS A CLINICIAN AND CLINICAL RESEARCHER Pharmacological Treatment of Any Disease • Know the Disease that you are treating • Nature; Treatment targets; Treatment goals; • Know the Treatments at your disposal • What they do; How they compare; Costs; • Principles of Treatment • Measurement-based; Targeted; Individualized Program Outline • Nature and Definition of psychosis? • Clinical description • What is wrong in psychotic illness • Dimensions of Psychopathology • Neurobiological Abnormalities • Mechanisms underlying antipsychotic effects? • What contributes to Efficacy • Basis of Side-effect differences 5 Challenges in DSM-IV Construct of Psychotic Disorders ♦ Indistinct Boundaries ♦ With Other Disorders (eg., with OCD) ♦ Within Group of Psychotic Disorders (eg. between
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]